Marc Martinell, PhD
Co-Founder & Chief Executive Officer
Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other Inborn Errors of Metabolism, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102) that has multiple CNS indications, has successfully completed a phase 1 clinical trial and is ready to move into a phase 2/3 study with adult AMN patients. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurological deterioration with no available pharmacological treatment.
Minoryx is also working on a new class of compounds; non-competitive pharmacological chaperones, identified through its innovative proprietary platform – SEE-Tx.
One of the biggest assets of the company is our team, a group of professionals fully committed to the task of delivering new treatments for rare diseases.
Minoryx and their employees are absolutely dedicated to relieving people’s suffering from rare diseases, especially children and their families.
We innovate by exploiting state of the art technologies. We form synergistic partnerships for drug discovery and provide them with an environment which fosters creativity and open-mindedness.
We strive to provide life-changing treatments for diseases with highly unmet medical needs.